LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

NCT04402957 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID
Severe Acute Respiratory Syndrome
Sars-CoV2
Acute Kidney Injury
Acute Respiratory Distress Syndrome

Interventions

DRUG: LSALT peptide
DRUG: Placebo

Sponsor

Arch Biopartners Inc.